Lung microwave ablation: Post-procedure imaging features and evolution of pulmonary ground-glass nodule-like lung cancer.


Journal

Journal of cancer research and therapeutics
ISSN: 1998-4138
Titre abrégé: J Cancer Res Ther
Pays: India
ID NLM: 101249598

Informations de publication

Date de publication:
01 Dec 2023
Historique:
received: 13 04 2023
accepted: 01 08 2023
medline: 2 1 2024
pubmed: 2 1 2024
entrez: 29 12 2023
Statut: ppublish

Résumé

To retrospectively examine the imaging characteristics of chest-computed tomography (CT) following percutaneous microwave ablation (MWA) of the ground-glass nodule (GGN)-like lung cancer and its dynamic evolution over time. From June 2020 to May 2021, 147 patients with 152 GGNs (51 pure GGNs and 101 mixed GGNs, mean size 15.0 ± 6.3 mm) were enrolled in this study. One hundred and forty-seven patients underwent MWA procedures. The imaging characteristics were evaluated at predetermined time intervals: immediately after the procedure, 24-48 h, 1, 3, 6, 12, and ≥18 months (47 GGNs). This study population included 147 patients with 152 GGNs, as indicated by the results: 43.5% (66/152) adenocarcinoma in situ, 41.4% (63/152) minimally invasive adenocarcinoma, and 15.1% (23/152) invasive adenocarcinoma. Immediate post-procedure tumor-level analysis revealed that the most common CT features were ground-glass opacities (93.4%, 142/152), hyperdensity within the nodule (90.7%, 138/152), and fried egg sign or reversed halo sign (46.7%, 71/152). Subsequently, 24-48 h post-procedure, ground-glass attenuations, hyperdensity, and the fried egg sign remained the most frequent CT findings, with incidence rates of 75.0% (114/152), 71.0% (108/152), and 54.0% (82/152), respectively. Cavitation, pleural thickening, and consolidation were less frequent findings. At 1 month after the procedure, consolidation of the ablation region was the most common imaging feature. From 3 to 12 months after the procedure, the most common imaging characteristics were consolidation, involutional parenchymal bands and pleural thickening. At ≥18 months after the procedure, imaging features of the ablation zone revealed three changes: involuting fibrosis (80.8%, 38/47), consolidation nodules (12.8%, 6/47), and disappearance (6.4%, 3/47). This study outlined the anticipated CT imaging characteristics of GGN-like lung cancer following MWA. Diagnostic and interventional radiologists should be familiar with the expected imaging characteristics and dynamic evolution post-MWA in order to interpret imaging changes with a reference image.

Identifiants

pubmed: 38156934
doi: 10.4103/jcrt.jcrt_837_23
pii: 01363817-202319060-00021
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1654-1662

Informations de copyright

Copyright © 2023 Copyright: © 2023 Journal of Cancer Research and Therapeutics.

Références

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209–49. doi: 10.3322/caac.21660.
Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: A time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond) 2021;41:1037–48. doi: 10.1002/cac2.12197.
Ye X, Fan W, Wang Z, Wang J, Wang H, Wang J, et al. Expert consensus on thermal ablation therapy of pulmonary subsolid nodules (2021 Edition). J Cancer Res Ther 2021;17:1141–56. doi: 10.4103/jcrt.jcrt_1485_21.
Huang G, Yang X, Li W, Wang J, Han X, Wei Z, et al. A feasibility and safety study of computed tomography-guided percutaneous microwave ablation: A novel therapy for multiple synchronous ground-glass opacities of the lung. Int J Hyperthermia 2020;37:414–22. doi: 10.1080/02656736.2020.1756467.
Ost D, Fein A. Management strategies for the solitary pulmonary nodule. Curr Opin Pulm Med 2004;10:272–8.
Hertzanu Y, Ye X. Computed tomography-guided percutaneous microwave ablation: A new weapon to treat ground-glass opacity-lung adenocarcinoma. J Cancer Res Ther 2019;15:265–6. doi: 10.4103/jcrt.JCRT_65_19.
Mazzone PJ, Lam L. Evaluating the patient with a pulmonary nodule: A review. JAMA 2022;327:264–73. doi: 10.1001/jama.2021.24287.
Shi L, Zhao J, Peng X, Wang Y, Liu L, Sheng M. CT-based radiomics for differentiating invasive adenocarcinomas from indolent lung adenocarcinomas appearing as ground-glass nodules: A systematic review. Eur J Radiol 2021;144:109956. doi: 10.1016/j.ejrad.2021.109956.
Succony L, Rassl DM, Barker AP, McCaughan FM, Rintoul RC. Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies. Cancer Treat Rev 2021;99:102237. doi: 10.1016/j.ctrv.2021.102237.
Chen X, Yao B, Li J, Liang C, Qi R, Yu J. Feasibility of using high-resolution computed tomography features for invasiveness differentiation of malignant nodules manifesting as ground-glass nodules. Can Respir J 2022;2022:2671772. doi: 10.1155/2022/2671772.
Shigefuku S, Shimada Y, Hagiwara M, Kakihana M, Kajiwara N, Ohira T, et al. Prognostic significance of ground-glass opacity components in 5-Year survivors with resected lung adenocarcinoma. Ann Surg Oncol 2021;28:148–56. doi: 10.1245/s10434-020-09125-x.
Meng Y, Liu CL, Cai Q, Shen YY, Chen SQ. Contrast analysis of the relationship between the HRCT sign and new pathologic classification in small ground glass nodule-like lung adenocarcinoma. Radiol Med 2019;124:8–13. doi: 10.1007/s11547-018-0936-x.
Mironova V, Blasberg JD. Evaluation of ground glass nodules. Curr Opin Pulm Med 2018;24:350–4. doi: 10.1097/MCP.0000000000000492.
Migliore M, Fornito M, Palazzolo M, Criscione A, Gangemi M, Borrata F, et al. Ground glass opacities management in the lung cancer screening era. Ann Transl Med 2018;6:90. doi: 10.21037/atm.2017.07.28.
Sihoe ADL. Should sublobar resection be offered for screening-detected lung nodules? Transl Lung Cancer Res 2021;10:2418–26. doi: 10.21037/tlcr.2020.04.06.
Lin MW, Chen JS. Image-guided techniques for localizing pulmonary nodules in thoracoscopic surgery. J Thorac Dis 2016;8(Suppl 9):S749–55. doi: 10.21037/jtd.2016.09.71.
Páez-Carpio A, Gómez FM, Isus Olivé G, Paredes P, Baetens T, Carrero E, et al. Image-guided percutaneous ablation for the treatment of lung malignancies: Current state of the art. Insights Imaging 2021;12:57. doi: 10.1186/s13244-021-00997-5.
Murphy MC, Wrobel MM, Fisher DA, Cahalane AM, Fintelmann FJ. Update on image-guided thermal lung ablation: Society guidelines, therapeutic alternatives, and postablation imaging findings. AJR Am J Roentgenol 2022;219:471–85. doi: 10.2214/AJR.21.27099.
Yang X, Ye X, Lin Z, Jin Y, Zhang K, Dong Y, et al. Computed tomography-guided percutaneous microwave ablation for treatment of peripheral ground-glass opacity-lung adenocarcinoma: A pilot study. J Cancer Res Ther 2018;14:764–71. doi: 10.4103/jcrt.JCRT_269_18.
Chi J, Wang Z, Ding M, Hu H, Zhai B. Technical safety and efficacy of a blunt-tip microwave ablation electrode for CT-guided ablation of pulmonary ground-glass opacity nodules. Eur Radiol 2021;31:7484–90. doi: 10.1007/s00330-021-07774-4.
Wu J, Bai HX, Chan L, Su C, Zhang PJ, Yang L, et al. Sublobar resection compared with stereotactic body radiation therapy and ablation for early stage non-small cell lung cancer: A national cancer database study. J Thorac Cardiovasc Surg 2020;160:1350–7. doi: 10.1016/j.jtcvs.2019.11.132.
Xue G, Li Z, Wang G, Wei Z, Ye X. Computed tomography-guided percutaneous microwave ablation for pulmonary multiple ground-glass opacities. J Cancer Res Ther 2021;17:811–3. doi: 10.4103/jcrt.jcrt_531_21.
Vespro V, Bonanno MC, Andrisani MC, Ierardi AM, Phillips A, Tosi D, et al. CT after lung microwave ablation: Normal findings and evolution patterns of treated lesions. Tomography 2022;8:617–26. doi: 10.3390/tomography8020051.
Araujo-Filho JAB, Menezes RSAA, Horvat N, Panizza PSB, Bernardes JPG, Damasceno RS, et al. Lung radiofrequency ablation: Post-procedure imaging patterns and late follow-up. Eur J Radiol Open 2020;7:100276. doi: 10.1016/j.ejro.2020.100276.
Hata A, Schiebler ML, Lynch DA, Hatabu H. Interstitial lung abnormalities: State of the art. Radiology 2021;301:19–34. doi: 10.1148/radiol.2021204367.
Wang J, Ni Y, Yang X, Huang G, Wei Z, Li W, et al. Diagnostic ability of percutaneous core biopsy immediately after microwave ablation for lung ground-glass opacity. J Cancer Res Ther 2019;15:755–9. doi: 10.4103/jcrt.JCRT_399_19.
Sparchez Z, Mocan T, Hajjar NA, Bartos A, Hagiu C, Matei D, et al. Percutaneous ultrasound guided radiofrequency and microwave ablation in the treatment of hepatic metastases. A monocentric initial experience. Med Ultrason 2019;21:217–24. doi: 10.11152/mu-1957.
Liu S, Zhu X, Qin Z, Xu J, Zeng J, Chen J, et al. Computed tomography-guided percutaneous cryoablation for lung ground-glass opacity: A pilot study. J Cancer Res Ther 2019;15:370–4. doi: 10.4103/jcrt.JCRT_299_18.
Liu B, Ye X. Computed tomography-guided percutaneous microwave ablation: A novel perspective to treat multiple pulmonary ground-glass opacities. Thorac Cancer 2020;11:2385–8. doi: 10.1111/1759-7714.13601.
Chen J, Lin XN, Miao XH, Chen J, Lin RX, Su HY, et al. Evaluation of the correlation between infrared thermal imaging-magnetic resonance imaging-pathology of microwave ablation of lesions in rabbit lung tumors. J Cancer Res Ther 2020;16:1129–33. doi: 10.4103/0973-1482.296428.
Lin R, Fang Y, Chen J, Lin Q, Chen J, Yan Y, et al. MR-guided microwave ablation for lung malignant tumor: A single center prospective study. Front Oncol 2022;12:856340. doi: 10.3389/fonc.2022.856340.
Shang Y, Li G, Zhang B, Wu Y, Chen Y, Li C, et al. Image-guided percutaneous ablation for lung malignancies. Front Oncol 2022;12:1020296. doi: 10.3389/fonc.2022.1020296.
Frandon J, Akessoul P, Kammoun T, Dabli D, de Forges H, Beregi JP, et al. Microwave ablation of liver, kidney and lung lesions: One-month response and manufacturer’s charts’ reliability in clinical practice. Sensors (Basel) 2022;22:3973. doi: 10.3390/s22113973.
Chheang S, Abtin F, Guteirrez A, Genshaft S, Suh R. Imaging features following thermal ablation of lung malignancies. Semin Intervent Radiol 2013;30:157–68. doi: 10.1055/s-0033-1342957.
Ahrar K, Tam AL, Kuban JD, Wu CC. Imaging of the thorax after percutaneous thermal ablation of lung malignancies. Clin Radiol 2022;77:31–43. doi: 10.1016/j.crad.2021.07.007.
Ye X, Fan W, Wang Z, Wang J, Wang H, Niu L, et al. Clinical practice guidelines on image-guided thermal ablation of primary and metastatic lung tumors (2022 edition). J Cancer Res Ther 2022;18:1213–30. doi: 10.4103/jcrt.jcrt_880_22.
Liu B, Li C, Sun X, Zhou W, Sun J, Liu H, et al. Assessment and prognostic value of immediate changes in post-ablation intratumor density heterogeneity of pulmonary tumors via radiomics-based computed tomography features. Front Oncol 2021;11:615174. doi: 10.3389/fonc.2021.615174.
Alberti N, Buy X, Frulio N, Montaudon M, Canella M, Gangi A, et al. Rare complications after lung percutaneous radiofrequency ablation: Incidence, risk factors, prevention and management. Eur J Radiol 2016;85:1181–91. doi: 10.1016/j.ejrad.2016.03.032.
Wei Z, Ye X, Yang X, Huang G, Li W, Wang J, et al. Advanced non small cell lung cancer: Response to microwave ablation and EGFR Status. Eur Radiol 2017;27:1685–94. doi: 10.1007/s00330-016-4474-4.
Wei Z, Ye X, Yang X, Zheng A, Huang G, Li W, et al. Microwave ablation in combination with chemotherapy for the treatment of advanced non-small cell lung cancer. Cardiovasc Intervent Radiol 2015;38:135–42. doi: 10.1007/s00270-014-0895-0.
Wei Z, Ye X, Yang X, Huang G, Li W, Han X, et al. Efficacy and safety of microwave ablation in the treatment of patients with oligometastatic non-small-cell lung cancer: A retrospective study. Int J Hyperthermia 2019;36:827–34. doi: 10.1080/02656736.2019.1642522.
Wei Z, Yang X, Ye X, Feng Q, Xu Y, Zhang L, et al. Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: A multicenter, randomized, controlled, phase III clinical trial. Eur Radiol 2020;30:2692–702. doi: 10.1007/s00330-019-06613-x.
Yang X, Ye X, Zhang L, Geng D, Du Z, Yu G, et al. Microwave ablation for lung cancer patients with a single lung: Clinical evaluation of 11 cases. Thorac Cancer 2018;9:548–54. doi: 10.1111/1759-7714.12611.
Watson RA, Tol I, Gunawardana S, Tsakok MT. Is microwave ablation an alternative to stereotactic ablative body radiotherapy in patients with inoperable early-stage primary lung cancer? Interact Cardiovasc Thorac Surg 2019;29:539–43. doi: 10.1093/icvts/ivz123.

Auteurs

Guoliang Xue (G)

Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China.

Wenjing Jia (W)

Department of Radiology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Abdominal Medical Imaging, Shandong Lung Cancer Institute, Shandong Institute of Neuroimmunology, Jinan, China.

Gang Wang (G)

Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China.

Qingshi Zeng (Q)

Department of Radiology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Abdominal Medical Imaging, Shandong Lung Cancer Institute, Shandong Institute of Neuroimmunology, Jinan, China.

Nan Wang (N)

Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China.

Zhichao Li (Z)

Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China.

Pikun Cao (P)

Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China.

Yanting Hu (Y)

Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China.

Jie Xu (J)

Department of Radiology, Guangrao County People's Hospital, Dongying, Shandong Province, China.

Zhigang Wei (Z)

Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China.

Xin Ye (X)

Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China.

Classifications MeSH